The MNPs used here traverse the BBB and deliver two different kinds of anticancer agents to the GBM cells: RNA therapeutics, that is, AON inhibitors of EGFR/EGFRvIII and c-Myc (regulators of many tumorigenic events and immunostimulators), or a checkpoint PD-1 inhibitor antibody (αPD-1) to prevent immune suppression. This evidence concerns the gene MYC and glioblastoma.